(Q50711021)

18 March 2018

title

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. (English)

1 reference

18 March 2018

magnetic resonance imaging

main subject

0 references

author name string

M Lewańska

series ordinal

1

1 reference

18 March 2018

M Siger-Zajdel

series ordinal

2

1 reference

18 March 2018

K Selmaj

series ordinal

3

1 reference

18 March 2018

publication date

1 November 2002

1 reference

18 March 2018

European Journal of Neurology

published in

1 reference

18 March 2018

volume

9

1 reference

18 March 2018

page(s)

565-572

1 reference

18 March 2018

issue

6

1 reference

18 March 2018

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Complications of intravenous immune globulin treatment in neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

MS: a CNS and systemic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

High-dose intravenous immunoglobulin therapy for myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

From enhancing lesions to brain atrophy in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00500.X

10.1046/J.1468-1331.2002.00500.X

21 January 2018

Identifiers

DOI

1 reference

18 March 2018

PubMed ID

12453070

1 reference

18 March 2018